Tags

Type your tag names separated by a space and hit enter

Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2.
Blood. 2021 May 14 [Online ahead of print]Blood

Abstract

Vaccination using the adenoviral vector COVID-19 vaccine ChAdOx1 nCoV-19 (AstraZeneca) has been associated with rare vaccine-induced immune thrombotic thrombocytopenia (VITT). Affected patients test strongly positive in PF4/polyanion enzyme immunoassays (EIAs) and serum-induced platelet activation is maximal in the presence of PF4. We determined the frequency of anti-PF4/polyanion antibodies in healthy vaccinees and assessed whether PF4/polyanion EIA-positive sera exhibit platelet-activating properties after vaccination with ChAdOx1 nCoV-19 (n=138) or BNT162b2 (BioNTech/Pfizer; n=143). In total, 19 of 281 participants tested positive for anti-PF4/polyanion antibodies post-vaccination (All: 6.8% [95%CI, 4.4-10.3]; BNT162b2: 5.6% [95%CI, 2.9-10.7]; ChAdOx1 nCoV-19: 8.0% [95%CI, 4.5-13.7%]). Optical densities were mostly low (between 0.5-1.0 units; reference range, <0.50) and none of the PF4/polyanion EIA-positive samples induced platelet activation in the presence of PF4. We conclude that positive PF4/polyanion EIAs can occur after SARS-CoV-2 vaccination with both mRNA- and adenoviral vector-based vaccines, but the majority of these antibodies likely have minor (if any) clinical relevance. Accordingly, low-titer positive PF4/polyanion EIA results should be interpreted with caution when screening asymptomatic individuals after vaccination against Covid-19. Pathogenic platelet-activating antibodies that cause VITT do not occur commonly following vaccination.

Authors+Show Affiliations

Institut für Immunologie und Transfusionsmedizin, Greifswald, Germany.University Medicine Greifswald, Greifswald, Germany.Universitätsmedizin Greifswald, Greifswald, Germany.University Medicine Greifswald, Greifswald, Germany.Universitätsmedizin Greifswald, Greifswald, Germany.Universitätsmedizin Greifswald, Greifswald, Germany.McMaster University, Hamilton, Ontario, Canada.Universitätsmedizin Greifswald, Greifswald, Germany.University Medicine Greifswald, Greifswald, Germany.Universitätsmedizin Greifswald, Greifswald, Germany.University Medicine Greifswald, Institute of Immunology and Transfusion Medicine, Greifswald, Germany.University Medicine Greifswald, Zentralbereich Hygiene, Greifswald, Germany.University Medicine Greifswald, Greifswald, Germany.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

33988688

Citation

Thiele, Thomas, et al. "Frequency of Positive anti-PF4/polyanion Antibody Tests After COVID-19 Vaccination With ChAdOx1 nCoV-19 and BNT162b2." Blood, 2021.
Thiele T, Ulm L, Holtfreter S, et al. Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2. Blood. 2021.
Thiele, T., Ulm, L., Holtfreter, S., Schönborn, L., Kuhn, S. O., Scheer, C., Warkentin, T. E., Bröker, B., Becker, K., Aurich, K., Selleng, K., Hübner, N. O., & Greinacher, A. (2021). Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2. Blood. https://doi.org/10.1182/blood.2021012217
Thiele T, et al. Frequency of Positive anti-PF4/polyanion Antibody Tests After COVID-19 Vaccination With ChAdOx1 nCoV-19 and BNT162b2. Blood. 2021 May 14; PubMed PMID: 33988688.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2. AU - Thiele,Thomas, AU - Ulm,Lena, AU - Holtfreter,Silva, AU - Schönborn,Linda, AU - Kuhn,Sven Olaf, AU - Scheer,Christian, AU - Warkentin,Theodore E, AU - Bröker,Barbara, AU - Becker,Karsten, AU - Aurich,Konstanze, AU - Selleng,Kathleen, AU - Hübner,Nils-Olaf, AU - Greinacher,Andreas, Y1 - 2021/05/14/ PY - 2021/05/11/accepted PY - 2021/04/22/received PY - 2021/05/08/revised PY - 2021/5/14/entrez PY - 2021/5/15/pubmed PY - 2021/5/15/medline JF - Blood JO - Blood N2 - Vaccination using the adenoviral vector COVID-19 vaccine ChAdOx1 nCoV-19 (AstraZeneca) has been associated with rare vaccine-induced immune thrombotic thrombocytopenia (VITT). Affected patients test strongly positive in PF4/polyanion enzyme immunoassays (EIAs) and serum-induced platelet activation is maximal in the presence of PF4. We determined the frequency of anti-PF4/polyanion antibodies in healthy vaccinees and assessed whether PF4/polyanion EIA-positive sera exhibit platelet-activating properties after vaccination with ChAdOx1 nCoV-19 (n=138) or BNT162b2 (BioNTech/Pfizer; n=143). In total, 19 of 281 participants tested positive for anti-PF4/polyanion antibodies post-vaccination (All: 6.8% [95%CI, 4.4-10.3]; BNT162b2: 5.6% [95%CI, 2.9-10.7]; ChAdOx1 nCoV-19: 8.0% [95%CI, 4.5-13.7%]). Optical densities were mostly low (between 0.5-1.0 units; reference range, <0.50) and none of the PF4/polyanion EIA-positive samples induced platelet activation in the presence of PF4. We conclude that positive PF4/polyanion EIAs can occur after SARS-CoV-2 vaccination with both mRNA- and adenoviral vector-based vaccines, but the majority of these antibodies likely have minor (if any) clinical relevance. Accordingly, low-titer positive PF4/polyanion EIA results should be interpreted with caution when screening asymptomatic individuals after vaccination against Covid-19. Pathogenic platelet-activating antibodies that cause VITT do not occur commonly following vaccination. SN - 1528-0020 UR - https://www.unboundmedicine.com/medline/citation/33988688/Frequency_of_positive_anti_PF4/polyanion_antibody_tests_after_COVID_19_vaccination_with_ChAdOx1_nCoV_19_and_BNT162b2_ L2 - https://linkinghub.elsevier.com/retrieve/pii/475972 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.